After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

A gene-matched Alzheimer’s drug that slows early symptoms is now approved for use. Patients will need genetic screening, fortnightly infusions, and regular brain scans to stay on treatment.

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Japan’s Eisai and US biotech major Biogen have announced that the latest findings demonstrating the benefits of continuous ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

The drug is called Leqembi, and it removes plaques in the brain that are associated with Alzheimer's. After about 18 months, ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's ...